Welcome to our dedicated page for HELIX ACQUISITION III news (Ticker: HLXC), a resource for investors and traders seeking the latest updates and insights on HELIX ACQUISITION III stock.
Helix Acquisition Corp. III news covers the company's activity as a Nasdaq-listed special purpose acquisition company. Recurring developments include its initial public offering, Class A ordinary share listing, sponsor private placement, trust-account funding, and capital-structure details tied to its blank-check company model.
The company's news also describes its stated purpose of pursuing a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, with an intended focus on healthcare or healthcare-related industries.
Helix Acquisition Corp. III (Nasdaq: HLXC) closed its initial public offering on January 26, 2026, selling 17,250,000 Class A ordinary shares at $10.00 per share, including the full 2,250,000‑share over‑allotment, producing $172,500,000 gross proceeds before underwriting discounts and offering expenses. Concurrently the sponsor purchased 497,500 Class A shares in a private placement at $10.00 for $4,975,000. The Class A shares began trading on Nasdaq under HLXC on January 23, 2026. A total of $172,500,000 of net proceeds from the IPO and private placement was placed in trust. An audited balance sheet as of January 26, 2026 will be filed on Form 8‑K.
Helix Acquisition Corp. III (NASDAQ: HLXC) priced an upsized initial public offering of 15,000,000 Class A ordinary shares at $10.00 per share, implying gross proceeds of approximately $150 million. The shares begin trading on The Nasdaq Global Market under the ticker HLXC on January 23, 2026, and the company expects to consummate the offering on January 26, 2026.
The sponsor is Helix Holdings III LLC, affiliated with Cormorant Asset Management, with management led by Bihua Chen (CEO and chair) and Caleb Tripp (CFO and COO). Leerink Partners and Oppenheimer & Co. are joint bookrunners. The underwriters have a 45-day option to purchase up to an additional 2,250,000 shares to cover over-allotments.